Compare · CLDI vs GILD
CLDI vs GILD
Side-by-side comparison of Calidi Biotherapeutics Inc. (CLDI) and Gilead Sciences Inc. (GILD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLDI and GILD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $195.13B, about 60844.5x CLDI ($3.2M).
- Over the past year, CLDI is down 96.9% and GILD is up 26.9% - GILD leads by 123.8 points.
- GILD has hit the wire 5 times in the past 4 weeks while CLDI has been quiet.
- GILD has more recent analyst coverage (25 ratings vs 2 for CLDI).
- Company
- Calidi Biotherapeutics Inc.
- Gilead Sciences Inc.
- Price
- $0.79-9.18%
- $156.22-0.76%
- Market cap
- $3.2M
- $195.13B
- 1M return
- -35.77%
- +3.48%
- 1Y return
- -96.93%
- +26.88%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- AMEX
- NASDAQ
- IPO
- 2021
- 1992
- News (4w)
- 0
- 5
- Recent ratings
- 2
- 25
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Latest CLDI
- SEC Form 8-K filed by Calidi Biotherapeutics Inc.
- Calidi Biotherapeutics Received NYSE American Notification Letter Regarding Stockholders’ Equity Deficiency
- Calidi Biotherapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events
- SEC Form 424B5 filed by Calidi Biotherapeutics Inc.
- Calidi Biotherapeutics Announces $1.2 Million Registered Direct Offering
- Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- SEC Form 4 filed by Chief Financial Officer Jackson Andrew C.
- SEC Form 4 filed by Chief Scientific Officer Fernandez Santidrian Antonio
- SEC Form 4 filed by Director Schoeneck James A
- SEC Form 4 filed by Director Leftwich Scott
Latest GILD
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 4 filed by Gilead Sciences Inc.
- SEC Form 144 filed by Gilead Sciences Inc.
- Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- Chairman & CEO O'Day Daniel Patrick sold $2,218,508 worth of shares (15,000 units at $147.90) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 566,683 units (SEC Form 4)
- SVP, Controllership Burkhart Erin converted options into 2,223 shares and covered exercise/tax liability with 768 shares (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $435,870 worth of shares (3,000 units at $145.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 164,096 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $432,646 worth of shares (3,000 units at $144.22) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 116,684 units (SEC Form 4)
- A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat
- Chief Financial Officer Dickinson Andrew D converted options into 2,797 shares and covered exercise/tax liability with 1,347 shares, increasing direct ownership by 0.88% to 167,096 units (SEC Form 4)